James Korolewicz

Feb 17, 2023 | jhep-reports.eu | Bernhard Scheiner |Alessandra Gennari |James Korolewicz |Charalampos-Vlasios Stikas

AbstractBackground and AimsDirect comparisons across first-line regimens for advanced hepatocellular carcinoma (HCC) are not available. We performed a network metanalysis of phase III of trials to compare first-line systemic treatments for HCC in terms of overall survival (OS), progression free survival (PFS), objective response rate (ORR), disease control rate (DCR) and incidence of adverse events (AEs).